search
pharmaceutical industry
Trends
- 1GLP-1 drugs shift from obesity medicine to lifestyle products▼Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.
- 2EU Council adopts sweeping overhaul of pharmaceutical rules▼‘Pharma package’: Council adopts new rules for a fairer and more competitive EU pharmaceutical sector
The Council of the European Union has adopted new legislation aimed at making the EU pharmaceutical sector fairer and more competitive. The so-called pharma package reforms the framework for medicines in the bloc, touching on access, availability and the attractiveness of Europe as a place to develop and produce drugs. It marks a major step in the EU's effort to modernise rules that have been in place for two decades.
- 3Kobayashi Pharmaceutical weighs buyout worth over ¥500 billion●Kobayashi Pharmaceutical, the firm that was at the center of a supplement contamination scandal involving suspected deat
Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The move would mark a major development for a company whose reputation and finances were badly damaged by the scandal, and market watchers are closely following what a takeover could mean for its future.
- 4China to build robot, car and pharmaceutical plants in Kazakhstan▼China to launch robot, car and pharmaceutical plants in Kazakhstan
China plans to open new manufacturing facilities in Kazakhstan, including plants producing robots, cars and pharmaceuticals. The projects deepen economic and industrial cooperation between the two neighbours and fit Kazakhstan's push to attract foreign investment and diversify its economy beyond raw materials. The announcement is drawing attention across regional media as a sign of expanding Chinese industrial presence in Central Asia.
- 5European Capital Backs Colombian Biotech Firm for 250 Million Vaccines▼Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines
European investors are injecting capital into a Colombian biotechnology company with plans to produce 250 million vaccines. The deal positions Colombia as a growing player in global vaccine manufacturing and reflects Europe's interest in diversifying pharmaceutical production capacity beyond its borders, though details on the funding amount and timeline remain limited.
- 6Weight-loss jab maker's Vogue World sponsorship sparks concern▼‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Novo Nordisk, the maker of weight-loss injection Wegovy, is sponsoring Vogue World, and the partnership is drawing criticism from commentators who call it problematic. Critics argue that having a pharmaceutical weight-loss brand fund a major fashion event risks glamorising slimming jabs and reinforcing harmful body-image pressures in an industry already criticised for promoting thinness.
- 7WSJ warns U.S. tariffs are hurting American biotech●The U.S. Tariff Attack on U.S. Biotech https://www.wsj.com/opinion/the-u-s-tariff-attack-on-u-s-biotech-c3406b92?mod=rss
The Wall Street Journal's opinion section argues that U.S. tariff policy is damaging the domestic biotechnology industry, which the piece frames as an ironic case of Washington's trade measures attacking American companies. The article is being shared in economic and policy discussions, drawing attention to the tension between protectionist trade policy and the administration's stated goal of strengthening U.S. industrial and pharmaceutical sectors.
- 8
A new EU report warns that pharmaceutical rules under debate in Brussels could make it harder for patients to access medicines. Concerns centre on provisions said to affect availability of treatments across member states, with patient groups and industry watching closely as the EU's pharmaceutical legislation reform moves forward.
- 9
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 10Biosimilars Sector Poised for M&A Shake-Up as Patent Cliff Looms●Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A
Legal and industry analysts say the biosimilars market has reached an inflection point, with regulatory reform, a maturing patent litigation framework and an approaching wave of major biologic patent expirations reshaping merger and acquisition strategy. Commentators expect pharmaceutical companies to pursue deals to capture market share as blockbuster biologics lose exclusivity and cheaper biosimilar competition intensifies.